Global Blood Therapeutics Inc. Net Income per Employee (GBT), current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket
 


Global Blood Therapeutics Inc.  (NASDAQ: GBT)
 

Global Blood Therapeutics Net Income per Employee

GBT's Quarterly Results, Trends, Rankings, Statistics
Global Blood Therapeutics Inc. recorded a cumulative net loss of $-322 million during 12 month ending in the second quarter 2022.
The Healthcare sector has seen employees of 209 other companies achieving higher income per employee. While Global Blood Therapeutics's total ranking has deteriorated compared to the previous quarter from 0 to 3894.


What is Income per Employee Ratio?






GBT Net Income per Employee (Jun 30 2022)
II. Quarter
(Mar 31 2022)
I. Quarter
(Dec 31 2021)
IV. Quarter
(Sep 30 2021)
III. Quarter
(Jun 30 2021)
II. Quarter
Y / Y Net Income Change - - - - -
Net Income per Employee (TTM) $ -597,152 -573,304 -561,280 -513,548 -492,980
GBT's Total Ranking # 3894 # 0 # 0 # 0 # 0
Seq. Net Income Change - - - - -


GBT Net Income per Employee Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 210
Healthcare Sector # 573
Overall Market # 3894

Net Income per Employee Statistics
High Average Low
$ -176,681 $ -409,551 $ -597,152
(Jun 30 2017)   (Jun 30 2022)







Companies with similar Income per Employee for 12 month ending Jun 30 2022, within Healthcare Sector Income per Employee Income 12 month ending Jun 30 2022Number of Employees Jun 30 2022


Date modified: 2026-08-30T17:12:36+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.